Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Associated Therapies: -

Clinical Trials

Capecitabine With Digoxin for Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Digoxin

First Posted Date: 2013-06-26

Last Posted Date: 2018-02-22

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 16

Registration Number: NCT01887288

Locations: 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States

A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Baricitinib
Drug: Digoxin

First Posted Date: 2013-05-21

Last Posted Date: 2017-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT01859078

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma, Neoplasms

Interventions: Drug: Digoxin
Drug: Vemurafenib

First Posted Date: 2013-01-10

Last Posted Date: 2015-09-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 29

Registration Number: NCT01765569

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Digoxin

First Posted Date: 2013-01-09

Last Posted Date: 2020-01-31

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 6

Registration Number: NCT01763931

Locations: 🇺🇸
Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes

Phase 1

Completed

Conditions: Depression

Interventions: Drug: fluvoxamine
Drug: Digoxin

First Posted Date: 2012-10-11

Last Posted Date: 2015-09-01

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 14

Registration Number: NCT01704638

Locations: 🇸🇪
CPTU, Stockholm, Sweden

A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: aleglitazar
Drug: digoxin

First Posted Date: 2012-10-05

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT01701739

Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure

Phase 4

Completed

Conditions: Cardiac Failure

Interventions: Drug: Ivabradine
Drug: Digoxin

First Posted Date: 2012-10-04

Last Posted Date: 2013-11-11

Lead Sponsor: Cocco, Giuseppe, M.D.

Target Recruit Count: 22

Registration Number: NCT01699776

Locations: 🇨🇭
Cardiology office, Rheinfelden, Argovia, Switzerland

A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YM178 OCAS
Drug: Digoxin

First Posted Date: 2012-08-14

Last Posted Date: 2015-09-01

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 25

Registration Number: NCT01663961

Locations: 🇫🇷
SGS Aster, Paris, France

An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Rosuvastatin
Drug: Digoxin

First Posted Date: 2012-05-15

Last Posted Date: 2024-02-02

Lead Sponsor: Reata, a wholly owned subsidiary of Biogen

Target Recruit Count: 32

Registration Number: NCT01598363

Locations: 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States

Drug Interaction Study of Isavuconazole and Digoxin

Phase 1

Completed

Conditions: Pharmacokinetics of Isavuconazole
Pharmacokinetics of Digoxin
Healthy Volunteers

Interventions: Drug: Isavuconazole
Drug: digoxin

First Posted Date: 2012-04-20

Last Posted Date: 2015-09-01

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 24

Registration Number: NCT01582412

Locations: 🇺🇸
Parexel International, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy